Streamex Corp. · NASDAQ:STEX
Streamex — BioSig Technologies — Needham Annual Virtual Healthcare Conference 2021
17 slides from Streamex's conference presentation, Apr 12, 2021
Slide 1: BioSig Technologies - Needham Virtual Healthcare Conference
BioSig: technologies 20" Annual Needham Virtual Healthcare cad ence NASDAQ: BSGM
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements including statements that address activities, events or developments that BioSig expects, believes or anticipates will or may occur in the future, such as predictions of financial performance, approvals and launches by BioSig of new pr
Slide 3: Who We Are
Who We Are — NASDAQ: BSGM EP Tech Market estimated 13.5% CAGR Global EP Market Expected to be $12.2 Billion by 2026 34 Patents Issued or Allowed e First customer #1 center by volume in the U.S. Second customer voted #1 hospital in the world Razor & Blade Business Model FDA Cleared Unblinding of clin
Slide 4: Our Solution
Our Solution * Signal processing platform ¢ Intracardiac signals ¢ Customizable interface oe. * Artificial intelligence More Geen better decisions™ BioSig’ symeo.: ascm | 4 technologies
Slide 5: "Secret Sauce"
“Secret Sauce” Optimize signals for mapping, signal interpretation and during therapy delivery + Right Atrial Typical Flutter signals during ablation with optimized settings showing no RF noise and detailed signal attenuation es 19,20 es 17.18 cs 15,16 es 13,14 es 11,12— v0 9,10 u0 7.8 —~"k ~ duo 5,
Slide 6: Market Opportunity - PURE EP
Market Opportunity - PURE EP™ Complex Cardiac Ablation: U.S. 13.5% Growth Rate 3,425 (Estimated) Ep labs Total Global Addressable Market $2.0 Billion
Slide 7: Expanded Product Adoption, Experience, and a Growing Database
Expanded Product Adoption, Experience, and a Growing Database # PURE EP Procedures by Account #PhysicianUsers [Texas Cardiac Arrythmia Institute - Austin [Mayo Clinic 120 UNIV of Penn. 99 Mass General 13 Deborah Heart & Lung 61 |Overland Park - Kansas 62 [Memorial — South Bend, IN 28 Houston Methodi
Slide 8: PURE EP System - Customer Installations
PURE EP™ System — Customer Installations 2 3 a Hospital of the : Gor | 4 > University of Pennsylvania p A 4 \ Bs y Texas Cardiac Arrhythmia Institute svaot-ascu |
Slide 9: Business Model
Business Model Data Sets Modules Service Agreements ER ORE, CLEARLY BioSig’ symeo.: ascm | 9 technologes
Slide 10: Commercialization - Regions and Centers of Excellence
Commercialization — Regions and Centers of Excellence Florida 120 EP Programs 240 Labs Texas United States ¥ NST 220 EP Programs ; 440 Labs Northeast 175 EP Programs 400 Labs Revenue Potential $286 Million symo.: Bem | 10 Industry data and BioSig Technologies, Ine. estimates. Green pins denote iets
Slide 11: Highly Profitable Elective Procedure
Highly Profitable Elective Procedure EP procedures are clinically urgent EP is revenue generating + Delaying procedure increases stroke risk and + CV surgery and invasive cardiology have the highest worsens outcomes net annual revenue compared to all other service lines Median Revenues and Cost per
Slide 12: Clinical Data Catalysts
Clinical Data Catalysts Further establish the safety and effectiveness of the PURE EP™ System Multi-center: Mayo Clinic, Mass General, TCAI Enrollment Completion April 13, 2021* Abstract Acceptance Q2, 2021* Unblinding data to the public July 15, 2021* Heart Rhythm Society Presentation July 27, 2021
Slide 13: Physician Testimonies
Physician Testimonies “The PURE EP System does provide innovative design with greater resolution and greater bandwidth, which should allow for safer and more efficacious ablations in the future.” - K. Venkatachalam, M.D., Cardiac Electrophysiologist, Mayo Clinic oe | “The quality of the recording th
Slide 14: Market Value Inflection
Market Value Inflection $1,623 $1,756 $2,740 $3,105 } BioSig Source: FactSet Systems and BioSig Technologies’ estimates. Market cap and reenues in milios SYMBOL: BSGM “
Slide 15: Revenue Increase = Market Capitalization Increase
Revenue Increase = Market Capitalization Increase $3,500.0 $3,000.0 $2,500.0 $2,000.0 $1,500.0 5 2 i a & & z 2 5 = $1,000.0 $500.0 Market Capitalization & Revenue Analysis 2 BioSig Technologies J—e—Axonics Modulations |e—Nevro Corporation -e-Acutus Medical Stereotaxis, $0-10m =$15m =$30m $100m Reven
Slide 16: Management Team
Management Team Kenneth L. Londoner, MBA. Steve Chaussy, CPA Julie Stephenson, BSN, MBA Natasha Drapeau John Kowalski Olivier Chaudoir Ewald Riechert sBostong., )Bogaelitse SIEMENS Medtronic OL: BSGM
Slide 17: Value Drivers
Value Drivers * $28 million” in cash on the balance sheet and no debt * Expect to triple the customer base in 2021 * Targeting sequential revenue growth in 2021 ¢ Expect CE mark approval / EU entry 2022 ¢ Launched Al program — Mayo partnership * Expect presentation of data Q3 2021 [nasdaq ‘BSGM ~ te
BioSig Technologies — Needham Annual Virtual Healthcare Conference 2021 on 6ix